Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Venous thromboembolism

Do patients with pancreatic cancer benefit from prophylaxis?

    • Angiology
    • Gastroenterology and Hepatology
    • News
    • Oncology
    • RX
    • Studies
  • 3 minute read

Advanced pancreatic cancer is associated with a significantly increased risk of venous thromboembolism: within one year, approximately one fifth of patients suffer such a complication – with devastating consequences. What is the best way to protect this population? There are several studies on this. For example, the CONKO-004 study, which was finally published in May 2015 after a long wait, demonstrates the preventive efficacy of low-molecular-weight heparin (Enoxaparin®).

It has been adequately demonstrated that enoxaparin can prevent venous thromboembolism (VTE). Some smaller studies had also already shown a benefit in cancer patients. The authors of the CONKO-004 study from the Charité in Berlin were primarily interested in investigating the situation in outpatients with pancreatic cancer. For this purpose, they randomized a total of 312 individuals with histologically confirmed advanced pancreatic cancer into two groups: One with first-line outpatient chemotherapy and enoxaparin prophylaxis (daily 1 mg/kg bw) and one with chemotherapy alone (control arm). Chemotherapy consisted of gemcitabine, fluorouracil, folinic acid, and cisplatin in patients in good condition and with low creatinine, and only gemcitabine in those in poor condition and with elevated creatinine. After three months, all patients received gemcitabine and those in the study group received daily fixed 40 mg enoxaparin.

The results had been presented at a previous ASCO meeting and later supplemented with survival data. Meanwhile, after a long wait, they have appeared in the Journal of Clinical Oncology. The aim of the study was to determine the extent to which enoxaparin reduces the rate of VTE and whether there is also an effect on progression-free or overall survival.

Risk significantly reduced by prophylaxis

Among the 152 patients in the control group, 15 symptomatic VTE occurred within the first three months, compared with only two among the 160 subjects in the enoxaparin arm. Thus, the risk of VTE was significantly reduced by 88% with enoxaparin prophylaxis. Overall, after approximately one year, the cumulative incidence of symptomatic VTE was finally 15.1% (control) vs. 6.4% (enoxaparin, HR 0.40; 95% CI 0.19-0.83; p=0.01).

And what about the risk for severe bleeding? In fact, such cases were more frequent in the enoxaparin group, although not significantly: compared to the five major bleeding events in the control group, seven such complications occurred under heparin (HR 1.4; 95% CI 0.35-3.72; p=1.0).

No effect was seen in survival: Neither progression-free (HR1.06) nor overall survival (HR 1.01) differences reached significance.
The authors conclude that primary VTE prevention in outpatients with advanced pancreatic cancer is effective and well feasible. Administration of enoxaparin did not affect the efficacy of tumor treatment.

Open questions

Despite the final publication of the CONKO-004 results, important questions remain:

  • Which patients with advanced pancreatic cancer are eligible for VTE prophylaxis or how should the risk for VTE and the risk for bleeding be weighted in patient selection?
  • Which anticoagulant, dose, and therapeutic regimen is best to use in outpatients?

Because of the large variability with respect to individual risk, the limited number of large and good randomized-controlled trials, and the risk of bleeding complications, guidelines, e.g., those of ASCO, currently do not recommend routine thromboprophylaxis in outpatients, including those with advanced pancreatic cancer.

Source: Pelzer U, et al: Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J Clin Oncol 2015; doi: 10.1200/JCO.2014.55.1481 (Epub ahead of print).

 

InFo ONCOLOGY & HEMATOLOGY 2015; 3(7): 4-5.

Autoren
  • Andreas Grossmann
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • CONKO
  • Eoxaparin
  • Pancreatic Cancer
  • Thromboembolism
Previous Article
  • Laboratory medicine - prenatal medicine

New promising methods of prenatal diagnostics

  • Education
  • Gynecology
  • Pharmaceutical medicine
  • RX
View Post
Next Article
  • Non-small cell lung cancer

CheckMate 057 with promising results

  • News
  • Oncology
  • Pneumology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 4 min
  • Surgical interventions

What is necessary, what can be dispensed with?

    • Congress Reports
    • Gynecology
    • RX
    • Studies
    • Surgery
View Post
  • 6 min
  • Case study

Pemphigus – from diagnosis to therapy

    • Cases
    • Dermatology and venereology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Efficacy, safety and practical application

Phytotherapeutic options for endometriosis

    • General Internal Medicine
    • Gynecology
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 5 min
  • Anxiety disorders

New study on lavender oil extract in a long-term setting

    • RX
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • Psychiatry and psychotherapy
    • Studies
View Post
  • 12 min
  • Evidence, effectiveness and practical implications

Medicinal plants for allergic rhinitis

    • RX
    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • ORL
    • Pharmaceutical medicine
    • Phytotherapy
    • Studies
View Post
  • 15 min
  • Current status and future prospects

Cell and gene therapies in modern cardiology

    • Cardiology
    • Education
    • Genetics
    • RX
    • Studies
View Post
  • 14 min
  • Patient-oriented recommendations for action

Effect of heat on diabetes technology

    • RX
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Prevention and health care
    • Studies
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • RX
    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • Sports Medicine
    • Studies
    • Training with partner
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Pathomechanisms, secondary prevention and treatment options
  • 2
    Effect of heat on diabetes technology
  • 3
    Improved quality of care aims for satisfied patients
  • 4
    Dr. ChatGPT: Large language models in everyday clinical practice
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.

Notifications